Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07184086
PHASE1

A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

Sponsor: Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors but has previously been tested in humans. The study is split into 2 parts. In the first part of the study, participants will either get CagriSema or a weight loss diet (calorie reduced). In the second part of the study,all participants will get CagriSema. Which treatment participants get in the first part of the study is decided by chance. Like all medicines, the study medicine may have side effects. The study will last for about 1.5 years.

Official title: The Effect of Cagrilintide and Semaglutide Combination Treatment Compared to a Weight-loss Inducing Diet on Energy Metabolism in Persons Living With Obesity: an Open-label Randomised Study

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2025-09-26

Completion Date

2027-10-12

Last Updated

2025-10-08

Healthy Volunteers

No

Conditions

Interventions

DRUG

CagriSema (Cagrilintide B + semaglutide I)

Cagrilintide and semaglutide will be administered subcutaneously.

BEHAVIORAL

Low Energy Diet

Participants will receive dietary intervention as per diet intervention manual.

Locations (2)

Advent Health-Res Inst

Orlando, Florida, United States

Pennington Biomed Res Ctr

Baton Rouge, Louisiana, United States